Renu S. Eapen

Sep 2, 2024 | europeanurology.com | Sandy Figiel |Anthony Bates |David Braun |Renu S. Eapen |Markus Eckstein |Brandon Manley | +5 more

KeywordsGenomicsTranscriptomicsProteomicsUrological cancer1 IntroductionAlbert Einstein famously said: “Look deep into nature, and then you will understand everything better”, and although he wrote this 2 yr before Francis Crick and James Watson [1]1. Watson, J.D. ∙ Crick, F.H.C.Molecular structure of nucleic acids: a structure for deoxyribose nucleic acidNature. 1953; 171:737-738 discovered DNA, he may well have had genes in mind.

Nov 13, 2023 | urotoday.com | Renu S. Eapen

Read the Full Video TranscriptZach Klaassen: Hi, my name is Dr. Zach Klaassen. I'm a urologic oncologist at the Georgia Cancer Center in Augusta, Georgia. I'm joined today by Dr. Michael Hofman and Dr. Renu Eapen, both from Peter MacCallum Cancer Center. Thank you so much for joining us today. Renu Eapen: Thanks for having us, Zach. Michael Hofman: Pleasure. Zach Klaassen: So we are talking about LuTectomy today, and this is a very exciting trial.

Nov 13, 2023 | urotoday.com | Renu S. Eapen

Zach Klaassen hosts Michael Hofman and Renu Eapen to discuss the LuTectomy trial, published in European Urology. The trial explores the use of Lutetium-PSMA-617 as a neoadjuvant treatment in prostate cancer surgery. Initially, the trial included both radiation and surgical arms, but later focused solely on the surgical approach. The study enrolled high-risk prostate cancer patients, with 20 participants divided into two cohorts based on the dosage of lutetium-PSMA received.

Jul 11, 2023 | urotoday.com | Renu S. Eapen

Renu Eapen, a recipient of the PCF Young Investigator Award, details her groundbreaking project on early use of Lutetium PSMA for high-risk localized prostate cancer. The two-cohort clinical trial involves administering Lutetium PSMA upfront, followed by radical prostatectomy. An integral part of the study is the translational work, analyzing changes in the tumor microenvironment in response to Lutetium PSMA.